KRAS G12D mutation in Brunner gland adenoma

Authors

Mahatma Ortega, Pathology, George Washington University School of Public Health and Health Services, Washington, District of Columbia, USA.
Jessica Sparks, University of Louisville School of Medicine, Louisville, Kentucky, USA.
Jack Lichy, Department of Pathology, George Washington University, Washington, District of Columbia, USA.
Victor E. Nava, Department of Pathology, George Washington University, Washington, District of Columbia, USA vnava1@gwu.edu.

Document Type

Journal Article

Publication Date

1-27-2023

Journal

BMJ case reports

Volume

16

Issue

1

DOI

10.1136/bcr-2022-252160

Keywords

Gastroenterology; Genetics; Pathology

Abstract

Brunner gland lesions (BGLs) encompass benign proliferations of the homonymous glands and have been designated as hyperplasia, adenoma (BGA), hamartoma or nodule. In general terms, lesions larger than 0.5 cm are considered true neoplasia with unknown malignant potential and unclear pathogenesis. Genetic alterations have seldom been reported in BGL, and include SMAD4/DPC4 and LRIG1, but not KRAS (Kirsten rat sarcoma viral oncogene homologue) to the best of our knowledge.We present the case of a man in his 60s, evaluated for iron deficiency anaemia harbouring a 1.5 cm BGA found by duodenoscopy. Immunohistochemistry failed to reveal microsatellite instability, and next-generation sequencing revealed a KRAS G12D point mutation.

APA Citation

Ortega, Mahatma; Sparks, Jessica; Lichy, Jack; and Nava, Victor E., "KRAS G12D mutation in Brunner gland adenoma" (2023). GW Authored Works. Paper 2231.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/2231

Department

Pathology